A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.

Inclusion Criteria:

• Male subjects and female of non-childbearing potential subjects between the ages of 18 and 55.
• BMI between 18.5 to 32 kg/m2.
• Total body weight ≥40 kg and ≤120 kg.

Exclusion Criteria:

• Previous treatment with an antibody within 6 months prior to Day 1.
• Pregnant or nursing females; females of childbearing potential.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.